Citadel Advisors’s Abiomed Inc ABMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-26,300
| Closed | -$6.46M | – | 15828 |
|
|
2022
Q3 | $6.46M | Buy |
26,300
+4,600
| +21% | +$1.24M | ﹤0.01% | 3450 |
|
|
2022
Q2 | $5.37M | Sell |
21,700
-3,800
| -15% | -$1.03M | ﹤0.01% | 3664 |
|
|
2022
Q1 | $8.45M | Sell |
25,500
-42,900
| -63% | -$13.2M | ﹤0.01% | 3239 |
|
|
2021
Q4 | $24.6M | Buy |
68,400
+22,200
| +48% | +$7.5M | 0.01% | 1799 |
|
|
2021
Q3 | $15M | Sell |
46,200
-3,300
| -7% | -$1.12M | ﹤0.01% | 2424 |
|
|
2021
Q2 | $15.4M | Buy |
49,500
+10,000
| +25% | +$3.07M | ﹤0.01% | 2418 |
|
|
2021
Q1 | $12.6M | Sell |
39,500
-53,600
| -58% | -$17.2M | ﹤0.01% | 2638 |
|
|
2020
Q4 | $30.2M | Sell |
93,100
-15,700
| -14% | -$4.34M | 0.01% | 1386 |
|
|
2020
Q3 | $30.1M | Sell |
108,800
-18,200
| -14% | -$5.24M | 0.01% | 1223 |
|
|
2020
Q2 | $30.7M | Buy |
127,000
+13,500
| +12% | +$2.71M | 0.01% | 1149 |
|
|
2020
Q1 | $16.5M | Sell |
113,500
-16,900
| -13% | -$2.81M | 0.01% | 1394 |
|
|
2019
Q4 | $22.2M | Buy |
130,400
+3,400
| +3% | +$630K | 0.01% | 1380 |
|
|
2019
Q3 | $22.6M | Buy |
127,000
+40,000
| +46% | +$8.65M | 0.01% | 1358 |
|
|
2019
Q2 | $22.7M | Sell |
87,000
-20,900
| -19% | -$5.55M | 0.01% | 1317 |
|
|
2019
Q1 | $30.8M | Buy |
107,900
+13,700
| +15% | +$4.55M | 0.02% | 1002 |
|
|
2018
Q4 | $30.6M | Sell |
94,200
-10,700
| -10% | -$3.72M | 0.02% | 912 |
|
|
2018
Q3 | $47.2M | Buy |
104,900
+44,800
| +75% | +$17.7M | 0.02% | 796 |
|
|
2018
Q2 | $24.6M | Buy |
60,100
+32,700
| +119% | +$11.8M | 0.01% | 1149 |
|
|
2018
Q1 | $7.97M | Buy |
27,400
+16,200
| +145% | +$4.11M | ﹤0.01% | 1945 |
|
|
2017
Q4 | $2.1M | Buy |
11,200
+1,100
| +11% | +$205K | ﹤0.01% | 3572 |
|
|
2017
Q3 | $1.7M | Sell |
10,100
-4,000
| -28% | -$605K | ﹤0.01% | 3589 |
|
|
2017
Q2 | $2.02M | Sell |
14,100
-8,700
| -38% | -$1.17M | ﹤0.01% | 3155 |
|
|
2017
Q1 | $2.85M | Buy |
22,800
+4,100
| +22% | +$475K | ﹤0.01% | 2643 |
|
|
2016
Q4 | $2.11M | Buy |
18,700
+1,000
| +6% | +$116K | ﹤0.01% | 2893 |
|
|
2016
Q3 | $2.28M | Sell |
17,700
-200
| -1% | -$24K | ﹤0.01% | 2819 |
|
|
2016
Q2 | $1.96M | Sell |
17,900
-10,400
| -37% | -$1.03M | ﹤0.01% | 2774 |
|
|
2016
Q1 | $2.68M | Sell |
28,300
-2,200
| -7% | -$186K | ﹤0.01% | 2357 |
|
|
2015
Q4 | $2.75M | Buy |
30,500
+1,400
| +5% | +$119K | ﹤0.01% | 2422 |
|
|
2015
Q3 | $2.7M | Buy |
29,100
+12,900
| +80% | +$1.14M | ﹤0.01% | 2587 |
|
|
2015
Q2 | $1.06M | Buy |
16,200
+4,400
| +37% | +$292K | ﹤0.01% | 3884 |
|
|
2015
Q1 | $845K | Buy |
11,800
+7,700
| +188% | +$418K | ﹤0.01% | 4153 |
|
|
2014
Q4 | $156K | Buy |
+4,100
| New | +$129K | ﹤0.01% | 6254 |
|
|
2014
Q2 | – | Sell |
-2,100
| Closed | -$55K | – | 8417 |
|
|
2014
Q1 | $55K | Sell |
2,100
-1,700
| -45% | -$47K | ﹤0.01% | 6704 |
|
|
2013
Q4 | $102K | Sell |
3,800
-4,200
| -53% | -$104K | ﹤0.01% | 5596 |
|
|
2013
Q3 | $153K | Sell |
8,000
-7,100
| -47% | -$162K | ﹤0.01% | 5005 |
|
|
2013
Q2 | $326K | Buy |
+15,100
| New | +$303K | ﹤0.01% | 4224 |
|
Other funds holding ABMD
TRSOTSOK
BTI
IA
AW
HNB
Citadel Advisors's ABMD Position: Q4 2022 in Review
Citadel Advisors sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 2,005 shares — an estimated $493K sold.
Citadel Advisors first reported a position in ABMD in Q2 2013 and held it in 33 quarters. The position peaked at $79.6M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.
- Citadel Advisors reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 2,005 Abiomed Inc shares in Q4 2022, an estimated $493K.
- Citadel Advisors first reported a position in Abiomed Inc in Q2 2013 and held it in 33 quarters.
- Citadel Advisors's Abiomed Inc position peaked at $79.6M in Q3 2018.
- 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.